Mode
Text Size
Log in / Sign up
N/A Completed N=146 Randomized Treatment

Use of the Paradigm 722 System to Improve Glycemic Control in Adult and Adolescent Subjects With Type 1 Diabetes

Source: ClinicalTrials.gov NCT00211510 ↗
Enrolled (actual)
146
Serious AEs
15.1%
Results posted
Apr 2011
Primary outcomePrimary: Change in A1c From Baseline to 26 Weeks — -0.72; -0.58 Percent glycated hemoglobin

Summary

The purpose of this study is to determine whether Type 1 Diabetic subjects using the Paradigm 722 System, which is a glucose sensor-augmented insulin pump, can improve glycemic control when compared to subjects using the Paradigm 715 insulin pump only.

Outcome Measures

OutcomeResultp-value
PRIMARY
Change in A1c From Baseline to 26 Weeks
-0.72; -0.58 —
SECONDARY
Difference in Frequency of Severe Hypoglycemia From Baseline to Week 26
11; 3 —
SECONDARY
Changes in Hypoglycemia Area Under the Curve (AUC) From Baseline to Week 26
-0.07; 0.281 —
SECONDARY
Changes in Hyperglycemia Area Under the Curve (AUC) From Baseline to Week 26
-10.2; -9.2 —
SECONDARY
Glucose Sensor Accuracy as Measured in the 722 Group
95.9; NA —
SECONDARY
Problem Areas in Diabetes (PAID) Questionnaire Assessed and Compared Between Groups
-0.07; -0.22 —

Eligibility Criteria

Inclusion Criteria

  • Age 12 - 80 years
  • Type 1 Diabetes Mellitus diagnosed at least 1 year ago
  • Using insulin infusion pump for past 6 months minimum
  • Performing minimum 4 blood glucose tests per day
  • Agree to treat to A1c targets
  • Read and understand English

Exclusion Criteria

  • Pregnant or planning pregnancy
  • History of unresolved tape allergy or skin conditions
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00211510). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search